ORMALVI is indicated for the treatment of hyperkalemic periodic paralysis, hypokalemic periodic paralysis and related variants.¹ It is a carbonic anhydrase inhibitor, however the precise mechanism by which dichlorphenamide exerts its therapeutic effects in patients with Primary Periodic Paralysis is unknown.¹

ORMALVI is the same proven dichlorphenamide as KEVEYIS,² accompanied by Cycle Vita^TM, a dedicated support platform which may help your eligible** patients live with confidence in managing their condition.

For a patient diagnosed with Primary Periodic Paralysis you can print and send a completed enrollment form to Cycle Vita at hello@cyclevita.life or fax it to them at +1 (888) 385-8482.

Genetic testing is recommended as the first diagnostic step where there is a high clinical likelihood of a Primary Periodic Paralysis diagnosis.²

Only 60% to 70% of patients with Primary Periodic Paralysis receive a positive genetic test.²

For the remaining 30% to 40% of patients with Primary Periodic Paralysis, diagnosis can be based upon clinical presentation, potassium levels in your blood during attacks, and pattern abnormalities on long exercise testing.²

If a genetic test comes back negative, one or more of the following tests could be utilized to help reach a diagnosis or rule out Primary Periodic Paralysis:

Cycle Vita is our dedicated hub support program, which delivers product support** at every step.

As soon as Cycle Vita receives a completed enrollment form, we can provide individualized support to eligible** patients, such as access to treatment, financial and pharmacy support, as well as clinical education and medication administration support. We will reach out to you and your patient to take the next steps.

The Bridge Program is a free supply of ORMALVI that allows diagnosed patients to begin therapy immediately while Cycle Vita secures appropriate Benefit Verification and Prior Authorization. The Bridge Program may also be requested for existing patients who are temporarily experiencing disruption in therapy due to insurance coverage.

If your patient’s insurance situation changes, the patient must notify Cycle Vita immediately at +1 (888) 360-8482.

Commercially insured eligible patients who have been prescribed ORMALVI may pay as little as $0 in co-pay.**

To find out more about eligibility criteria please contact Cycle Vita on +1 (888) 360-8482.

The Cycle Vita team are just a phone call away. You can expect to hear from two types of people at Cycle Vita:

+1 (888) 360-8482 hello@cyclevita.life www.cyclevita.life

When your patient is prescribed ORMALVI they can expect financial, logistics and educational support, including:

Complete an ORMALVI enrollment form and either email it to our Cycle Vita team at hello@cyclevita.life or fax it to them at + 1 (888) 385-8482.

Once they receive the form, our expert team will take care of all the details so your patients can get started on their treatment as soon as possible.

Please use the enrollment form rather than your own prescription form to avoid delays. You can use the Rx Checklist to help you complete the enrollment form correctly. And remember to specify dispense as written (DAW) on every enrollment form to ensure that your patients receive ORMALVI and the support available through Cycle Vita.